Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) posted its quarterly earnings results on Thursday. The basic materials company reported ($2.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($1.31), FiscalAI reports. Arcadia Biosciences had a negative net margin of 48.15% and a positive return on equity of 37.36%. The business had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $1.60 million.
Arcadia Biosciences Price Performance
Arcadia Biosciences stock traded up $0.01 during mid-day trading on Thursday, reaching $1.07. 5,824 shares of the company traded hands, compared to its average volume of 30,662. The firm’s 50 day moving average price is $1.42 and its 200 day moving average price is $2.35. The firm has a market capitalization of $2.20 million, a price-to-earnings ratio of -0.62 and a beta of 0.52. Arcadia Biosciences has a 52-week low of $0.89 and a 52-week high of $6.71.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings raised Arcadia Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.
About Arcadia Biosciences
Arcadia Biosciences, Inc, founded in 2002 and headquartered in Davis, California, is an agricultural biotechnology company dedicated to developing crops and food ingredients that promote health and sustainability. By harnessing advanced genomics and precision‐breeding technologies, Arcadia creates proprietary trait platforms designed to enhance crop performance, nutritional value, and resilience to environmental stressors. The company’s scientific expertise focuses on non-transgenic approaches, enabling the delivery of novel traits without introducing foreign DNA.
Arcadia’s operations span two main segments: Crop Traits and Food Ingredients.
Featured Stories
- Five stocks we like better than Arcadia Biosciences
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
